Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
Abstract Chronic lymphocytic leukemia (CLL), a common type of B cell chronic lymphoproliferative disorder in adults, has witnessed enormous development in its treatment in recent years. New drugs such as ibrutinib, idelalisib, and venetoclax have achieved great success in treating relapsed and refra...
Main Authors: | Yixin Zou, Wei Xu, Jianyong Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-11-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13045-018-0676-3 |
Similar Items
-
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
by: Veronika Mancikova, et al.
Published: (2021-05-01) -
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
by: Mingxue Fan, et al.
Published: (2017-08-01) -
Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies
by: Hyeon Joo Yoo, et al.
Published: (2019-05-01) -
Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
by: Daniel Sur, et al.
Published: (2020-01-01) -
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
by: Shengnan Yu, et al.
Published: (2019-08-01)